$MDAI
Spectral AI, Inc. Stock $mdai

$mdai Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024040950 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$7.478M	$6.326M	$0.00
YoY Change
Cost Of Revenue	$4.164M	$3.381M	$2.897M
YoY Change	69.27%	16.71%
Gross Profit	$3.314M	$2.945M	$2.181M
YoY Change	85.04%	35.03%
Gross Profit Margin	44.32%	46.55%
Selling, General & Admin	$5.756M	$5.088M	$527.4K
YoY Change	290.07%	864.77%	13.39%
% of Gross Profit	173.69%	172.77%	24.18%
Research & Development		$4.300M	$4.000M
YoY Change		7.5%
% of Gross Profit		146.01%	183.4%
Depreciation & Amortization	$2.000K	$3.000K	$2.000K
YoY Change		50.0%
% of Gross Profit	0.06%	0.1%	0.09%
Operating Expenses	$5.756M	$4.300M	$527.4K
YoY Change	290.07%	715.35%	13.39%
Operating Profit	-$2.442M	-$2.143M	-$527.4K
YoY Change	65.49%	306.35%	13.39%
Interest Expense	-$15.00K	-$2.000K	-$747.6K
YoY Change	-125.6%	-99.73%	-109.94%
% of Operating Profit
Other Income/Expense, Net	-$353.0K	-$1.040M	-$788.4K
YoY Change	-189.55%	31.91%
Pretax Income	-$2.795M	-$3.183M	-$1.275M
YoY Change	173.26%	149.65%	-118.08%
Income Tax	$69.00K	$22.00K	$7.093K
% Of Pretax Income
Net Earnings	-$2.864M	-$3.205M	-$1.282M
YoY Change	177.18%	149.98%	-118.18%
Net Earnings / Revenue	-38.3%	-50.66%
Basic Earnings Per Share	-$0.16	-$0.19	-$0.27
Diluted Earnings Per Share	-$0.16	-$0.19	-$0.19
COMMON SHARES
Basic Shares Outstanding	17.48M shares	17.47M shares	13.19M shares
Diluted Shares Outstanding	17.60M shares	16.56M shares	13.19M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.88M	$10.16M	$541.8K
YoY Change	10138.12%	1774.54%	16.29%
Cash & Equivalents	$6.877M	$10.16M	$541.8K
Short-Term Investments	$35.00M
Other Short-Term Assets	$973.0K	$1.090M	$203.8K
YoY Change	473.64%	434.76%	-14.92%
Inventory	$267.0K	$228.0K
Prepaid Expenses	$1.249M	$1.581M	$203.8K
Receivables	$2.295M	$1.828M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$11.66M	$14.88M	$745.7K
YoY Change	1915.22%	1896.05%	5.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.000K	$9.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$4.667M
YoY Change			-98.16%
Other Assets
YoY Change
Total Long-Term Assets	$2.236M	$599.0K	$4.667M
YoY Change	-52.68%	-87.16%	-98.16%
TOTAL ASSETS
Total Short-Term Assets	$11.66M	$14.88M	$745.7K
Total Long-Term Assets	$2.236M	$599.0K	$4.667M
Total Assets	$13.90M	$15.48M	$5.413M
YoY Change	162.0%	186.06%	-97.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.403M	$3.306M
YoY Change
Accrued Expenses	$2.733M	$3.818M	$3.687M
YoY Change	-45.29%	3.56%	22.53%
Deferred Revenue	$1.315M
YoY Change
Short-Term Debt	$8.001M	$5.752M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.13M	$17.51M	$3.965M
YoY Change	205.17%	341.61%	31.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.036M		$10.04M
YoY Change	-78.89%		-12.59%
Total Long-Term Liabilities	$2.036M	$0.00	$10.04M
YoY Change	-78.89%	-100.0%	-12.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.13M	$17.51M	$3.965M
Total Long-Term Liabilities	$2.036M	$0.00	$10.04M
Total Liabilities	$18.16M	$17.51M	$14.00M
YoY Change	21.67%	25.05%	-3.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.90M	-$36.00M	-$13.41M
YoY Change	168.68%	168.54%
Common Stock	$2.000K	$2.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.265M	-$2.028M	-$13.40M
YoY Change
Total Liabilities & Shareholders Equity	$13.90M	$15.48M	$5.413M
YoY Change	162.0%	186.06%	-97.87%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.864M	-$3.205M	-$1.282M
YoY Change	177.18%	149.98%	-118.18%
Depreciation, Depletion And Amortization	$2.000K	$3.000K	$2.000K
YoY Change		50.0%
Cash From Operating Activities	-$5.362M	-$2.680M	-$243.2K
YoY Change	3937.35%	1001.99%	-19.87%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.082M	$8.049M	-$104.0K
YoY Change		-7839.42%
NET CHANGE
Cash From Operating Activities	-5.362M	-$2.680M	-$243.2K
Cash From Investing Activities
Cash From Financing Activities	2.082M	$8.049M	-$104.0K
Net Change In Cash	-3.280M	$5.367M	-$243.2K
YoY Change	2369.69%	-2306.85%
FREE CASH FLOW
Cash From Operating Activities	-$5.362M	-$2.680M	-$243.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2515 McKinney Avenue
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1000
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75201
CY2024Q1	dei	City Area Code CityAreaCode	(972)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	685-1260
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17482333	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10157000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4790000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1828000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2346000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	228000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	230000	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	283000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1581000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1452000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1090000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	801000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	14884000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9902000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	590000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	778000	usd
CY2024Q1	us-gaap	Assets Assets	15483000	usd
CY2023Q4	us-gaap	Assets Assets	10692000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3306000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2683000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3818000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4300000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2177000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2311000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	660000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	853000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	218000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	436000	usd
CY2024Q1	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	4534000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1798000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1818000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17511000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12401000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	17511000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	12401000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17482333	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17482333	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16294935	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16294935	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33953000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31065000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35993000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32788000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-2028000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1709000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15483000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10692000	usd
CY2024Q1	us-gaap	Revenues Revenues	6326000	usd
CY2023Q1	us-gaap	Revenues Revenues	5078000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	3381000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2897000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	2945000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2181000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5088000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5079000	usd
CY2024Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5088000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5079000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2143000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2898000	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	14000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	44000	usd
CY2024Q1	mdai	Borrowing Related Costs BorrowingRelatedCosts	276000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16000	usd
CY2024Q1	mdai	Fair Value Adjustment Of Notes Payable FairValueAdjustmentOfNotesPayable	-66000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-16000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	13000	usd
CY2024Q1	mdai	Transaction Costs Incurred In Connection With Warrant Liabilities TransactionCostsIncurredInConnectionWithWarrantLiabilities	848000	usd
CY2023Q1	mdai	Transaction Costs Incurred In Connection With Warrant Liabilities TransactionCostsIncurredInConnectionWithWarrantLiabilities	738000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1040000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-665000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3183000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3563000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3205000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3609000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16560298	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13190600	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	1000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3207000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3608000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1709000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	283000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2605000	usd
CY2024Q1	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	-2000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3205000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-2028000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11996000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300000	usd
CY2023Q1	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3609000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8688000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3205000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3609000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	3000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	283000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	300000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-188000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-173000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16000	usd
CY2024Q1	mdai	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	66000	usd
CY2024Q1	mdai	Costs From Issuance Of Common Stock CostsFromIssuanceOfCommonStock	147000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-518000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-410000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2000	usd
CY2023Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-230000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	129000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	128000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	289000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	12000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	697000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-741000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-482000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-271000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-134000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-193000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-93000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2680000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3755000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2667000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4600000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	218000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	104000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8049000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-104000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5367000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3858000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4790000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14174000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10157000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10316000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2023Q3	mdai	Common Stock Exchange Ratio Price CommonStockExchangeRatioPrice	10.31
CY2023Q3	mdai	Contract Value ContractValue	150000000	usd
CY2024Q1	mdai	Contract Inital Award Value ContractInitalAwardValue	54900000	usd
CY2023Q2	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	4000000	usd
CY2024Q1	us-gaap	Investment Company Increase From Payment By Affiliate And Gain Loss From Investment In Violation InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation	1000000	usd
CY2024Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36000000	usd
CY2024Q1	us-gaap	Other Notes Payable OtherNotesPayable	5800000	usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	400000	usd
CY2023Q4	mdai	Aggregate Gross Purchase Price AggregateGrossPurchasePrice	10000000	usd
CY2024Q1	us-gaap	Program Rights Obligations ProgramRightsObligations	30000000	usd
CY2024Q1	us-gaap	Prepaid Interest PrepaidInterest	12500000	usd
CY2024Q1	mdai	Pre Paid Advance Disbursed Amount PrePaidAdvanceDisbursedAmount	4600000	usd
CY2024Q1	mdai	Prepaid Advance Net Discount Amount PrepaidAdvanceNetDiscountAmount	400000	usd
CY2024Q1	mdai	Prepaid Advance Net Discount Percentage PrepaidAdvanceNetDiscountPercentage	0.08	pure
CY2024Q1	mdai	Percentage Of Shares Of Common Stock Issued PercentageOfSharesOfCommonStockIssued	0.1999	pure
CY2024Q1	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3000000	usd
CY2024Q1	mdai	Additional Development Amount AdditionalDevelopmentAmount	500000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span>The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, warrant liabilities, the fair value of short term notes payable, fair value of the B. Riley and Yorkville derivative instruments, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets, and income tax valuation allowances. Actual results could differ from these estimates.</span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Concentrations of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span>Financial instruments which potentially subject the Company to credit risk consist principally of cash and accounts receivable. Primarily all cash is held in US financial institutions which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risk on cash.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span>Additional credit risk is related to the Company’s concentration of receivables. As of March 31, 2024 and December 31, 2023, receivables were concentrated from one customer (which is a US. Government agency) representing 98% and 92% of total net receivables, respectively. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span>One customer (which is a U.S. government agency) accounted for 96% for the three months ended March 31, 2024 and 97% for the three months ended March 31, 2023 of the recognized research and development revenue.</span></p>
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	16000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	13000000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.5
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4300000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4000000	usd
CY2024Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	3400000	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2900000	usd
CY2024Q1	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	900000	usd
CY2023Q1	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	1100000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	2400000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	660000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	127000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	860000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	277000	usd
CY2024Q1	mdai	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiabilities	2024000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	-2374000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	660000	usd
CY2024Q1	mdai	Noncash Net Assets Assumed In Exchange For Common Stock NoncashNetAssetsAssumedInExchangeForCommonStock	-3034000	usd
CY2024Q1	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	200000	usd
CY2023Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	700000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1798000	usd
CY2024Q1	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	4534000	usd
CY2024Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	6332000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1818000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	47000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-20000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	129000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-16000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	113000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4600000	usd
CY2024Q1	mdai	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	66000	usd
CY2024Q1	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	4534000	usd
CY2024Q1	us-gaap	Revenues Revenues	6326000	usd
CY2023Q1	us-gaap	Revenues Revenues	5078000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2311000	usd
CY2024Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	572000	usd
CY2024Q1	mdai	Deferred Revenue Reductions DeferredRevenueReductions	706000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2177000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2157000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1910000	usd
CY2024Q1	mdai	Accrued Operating Expenses AccruedOperatingExpenses	1060000	usd
CY2023Q4	mdai	Accrued Operating Expenses AccruedOperatingExpenses	1563000	usd
CY2024Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	563000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	720000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	38000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	107000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3818000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4300000	usd
CY2024Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	218000	usd
CY2023Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	104000	usd
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5752000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	436000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	30000000	usd
CY2024Q1	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	12500000	usd
CY2024Q1	us-gaap	Cash Cash	4600000	usd
CY2024Q1	mdai	Discount Rate DiscountRate	0.08	pure
CY2024Q1	mdai	Percentage Of Shares Of Common Stock Issued PercentageOfSharesOfCommonStockIssued	0.1999	pure
CY2024Q1	mdai	Percentage Of Prepaid Advance PercentageOfPrepaidAdvance	0.92	pure
CY2024Q1	mdai	Percentage Of Prepaid Advance At Annual Rate PercentageOfPrepaidAdvanceAtAnnualRate	0	pure
CY2024Q1	mdai	Percentage Of Increase In Convertible Notes PercentageOfIncreaseInConvertibleNotes	0.18	pure
CY2024Q1	mdai	Installment Principal Amount InstallmentPrincipalAmount	750000	usd
CY2024Q1	mdai	Installment Premium Rate InstallmentPremiumRate	0.07	pure
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	300000	usd
CY2024Q1	us-gaap	Other Borrowings OtherBorrowings	300000	usd
CY2024Q1	us-gaap	Investments Investments	1000000	usd
CY2024Q1	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P12M
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	210000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	115000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue	12
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	600000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	58197	shares
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	205000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	194000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	105000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	59000	usd
CY2024Q1	mdai	Operating Lease Expenses OperatingLeaseExpenses	310000	usd
CY2023Q1	mdai	Operating Lease Expenses OperatingLeaseExpenses	253000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	42000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	352000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	253000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	683000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	683000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	660000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Shares Issued SharesIssued	1187398	shares
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	400000	usd
CY2024Q1	mdai	Service Fee Costs ServiceFeeCosts	100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.65
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	450000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.16
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	508197	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.97
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3578579	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.2
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8041000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3578579	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.2
CY2024Q1	mdai	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y3M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8041000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3126216	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.87
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6092000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.013	pure
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12594087	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4513363	shares
CY2024Q1	us-gaap	Advances To Affiliate AdvancesToAffiliate	1000000	usd
CY2024Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q1	mdai	Borrowing Related Costs BorrowingRelatedCosts		usd
CY2023Q1	mdai	Fair Value Adjustment Of Notes Payable FairValueAdjustmentOfNotesPayable		usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13190600	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16560298	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q1	mdai	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable		usd
CY2023Q1	mdai	Costs From Issuance Of Common Stock CostsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2024Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables		usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent		usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001833498
CY2024Q1	dei	Entity File Number EntityFileNumber	000-00000

Files In Submission

Name	View Source	Status
0001213900-24-040950-index-headers.html	Edgar Link	pending
0001213900-24-040950-index.html	Edgar Link	pending
0001213900-24-040950.txt	Edgar Link	pending
0001213900-24-040950-xbrl.zip	Edgar Link	pending
ea0205374-10q_spectral.htm	Edgar Link	pending
ea020537401ex31-1_spectral.htm	Edgar Link	pending
ea020537401ex31-2_spectral.htm	Edgar Link	pending
ea020537401ex32_spectral.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mdai-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
mdai-20240331_cal.xml	Edgar Link	unprocessable
mdai-20240331_def.xml	Edgar Link	unprocessable
mdai-20240331_lab.xml	Edgar Link	unprocessable
mdai-20240331_pre.xml	Edgar Link	unprocessable
ea0205374-10q_spectral_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDAI
Spectral AI, Inc. Stock $mdai

2024 Q2 Form 10-Q Financial Statement

#000121390024040950 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDAI Spectral AI, Inc. Stock $mdai

2024 Q2 Form 10-Q Financial Statement

#000121390024040950 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDAI
Spectral AI, Inc. Stock $mdai